Skip to main content

Table 1 Virus-specific tetramer/pentamer+ CD8+ T cells and IFNγ + CD8+ T cells in the lungs and spleens of mice following primary and secondary infections with the indicated viruses (% of total CD8+ cells)

From: Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection

 

Days after primary (secondary) infection

Lung

Spleen

  

Tet+CD8+/total CD8+, %

IFNγ+CD8+/total CD8+, %

Tet+CD8+/total CD8+, %

IFNγ+CD8+/total CD8+, %

Primary Infectiona

Mockb(N = 2)

8

2.3

0.03

0.52

0.14

RSVb(N = 5)

8

23 ± 2.2

5.8 ± 0.21

3.5 ± 0.32

3.2 ± 0.56

VV-M2 INb(N = 5)

8

15 ± 1.4

5.2 ± 0.56

3.8 ± 0.51

2.2 ± 0.22

VV-M2 IDb(N = 5)

8

21 ± 2.1

8.9 ± 1.0

8.7 ± 0.85

8.2 ± 1.3

Mockc(N = 2)

8

1.3

0.08

0.53

0.04

Fluc(N = 5)

8

30 ± 1.9

5.6 ± 0.25

3.4 ± 0.20

1.4 ± 0.18

Mockb(N = 2)

28

0.35

0.03

0.14

0.06

RSVb(N = 5)

28

4.2 ± 0.60

0.58 ± 0.07

1.4 ± 0.22

1.5 ± 0.27

VV-M2 INb(N = 5)

28

6.8 ± 0.76

0.87 ± 0.10

1.2 ± 0.13

1.1 ± 0.11

VV-M2 IDb(N = 5)

28

5.1 ± 0.70

1.9 ± 0.32

3.0 ± 0.50

4.2 ± 0.51

Mockc(N = 2)

28

0.46

0.01

0.30

0.07

Fluc(N = 5)

28

16 ± 2.7

1.8 ± 0.23

0.92 ± 0.14

0.53 ± 0.15

Secondary Infectiond

Mock; Mockb(N = 1)

42 (8)

0.30

0.46

0.16

0.34

Mock; RSVb(N = 5)

42 (8)

30 ± 2.7

6.6 ± 0.85

5.7 ± 0.84

5.6 ± 0.73

RSV; RSVb(N = 5)

42 (8)

53 ± 1.5

9.5 ± 0.57

3.3 ± 0.19

2.7 ± 0.46

RSV; VV-M2 INb(N = 5)

42 (8)

46 ± 0.75

11 ± 1.1

4.2 ± 0.48

2.9 ± 081

RSV; VV-M2 IDb(N = 5)

42 (8)

22 ± 2.0

5.9 ± 0.50

14 ± 3.3

9.7 ± 1.9

Mock; Mockc(N = 1)

42 (8)

1.1

0.62

1.1

0.08

Flu; Fluc(N = 5)

42 (8)

20 ± 1.8

4.5 ± 0.16

4.5 ± 0.86

3.3 ± 1.0

Mock; Mockb(N = 1)

62 (28)

0.21

0.38

0.31

0.49

Mock; RSVb(N = 5)

62 (28)

6.0 ± 0.68

2.0 ± 0.25

1.3 ± 0.15

1.3 ± 0.20

RSV; RSVb(N = 5)

62 (28)

11 ± 2.9

1.3 ± 0.33

3.1 ± 0.62

1.6 ± 0.33

RSV; VV-M2 INb(N = 5)

62 (28)

16 ± 1.8

3.6 ± 0.27

3.7 ± 0.28

2.6 ± 0.30

RSV; VV-M2 IDb(N = 5)

62 (28)

14 ± 2.0

6.7 ± 0.94

7.6 ± 077

9.2 ± 0.36

Mock; Mockc(N = 1)

62 (28)

1.5

0.40

2.8

0.30

Flu; Fluc(N = 5)

62 (28)

18 ± 3.8

2.6 ± 0.51

2.9 ± 0.36

1.5 ± 0.14

  1. aOn day 0, mice were infected with 105 PFU of RSV by the IN route, 105 PFU of VV-M2 by IN or ID route, or 104 PFU of influenza A virus (Flu) administered by the IN route. On days 8 and 28 post-infection, the animals were sacrificed and total PMC and splenocytes were isolated, stained for CD8 in combination with a virus-specific MHC class I tetramer/pentamer or intracellular IFNγ staining as described in the text, and analyzed by flow cytometry.
  2. bAnalyzed with the RSV-specific MHC class I tetramer.
  3. cAnalyzed with the influenza virus-specific MHC class I pentamer.
  4. dOn day 0, mice were infected with RSV or influenza virus by the IN route or were mock-infected. On day 34, the animals were secondarily infected with RSV by the IN route, VV-M2 by the IN or ID route, or influenza virus, as indicated. Viral doses are as described in footnote a. PMC or splenocytes were isolated on days 42 and 62 (8 and 28 days following the secondary infection), and analyzed as above.
Back to article page

Virology Journal

ISSN: 1743-422X